Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion.
Background. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show low-response to treatmentwith regard to visual acuity gain (VA) andOCT central retinal thickness (CRT) reduction. The goal of this study was to quantify the percentage of low-...
| Publicado en: | Journal of Ophthalmology pp. 1 - 7 |
|---|---|
| Autores principales: | , , , |
| Formato: | diagnostic images pictorial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119971543&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 119971543 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2090004X 9038 jtl: Journal of Ophthalmology issn: 2090004X maglogo: N pubinfo: dt: 2016 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 119971543 119971543 119971543 10.1155/2016/9875741 119971543 ppf: 1 ppct: 6 formats: tig: atl: Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion. aug: au: Menke, Marcel N. Ebneter, Andreas Zinkernagel, Martin S. Wolf, Sebastian affil: Department of Ophthalmology, Cantonal Hospital Aarau, Aarau, Switzerland sug: subj: Vascular Endothelial Growth Factors Antagonists and Inhibitors Retinal Vein Occlusion Visual Acuity Edema Computer Terminals Eye Prospective Studies Clinical Trials Observational Methods Surveys ab: Background. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show low-response to treatmentwith regard to visual acuity gain (VA) andOCT central retinal thickness (CRT) reduction. The goal of this study was to quantify the percentage of low-responders. Methods. Treatment of naïve eyes with macular edema secondary to RVO was included and monthly VA and CRT were analyzed. Four weeks after the loading phase, and at the end of the study, eyes were grouped into low- and good responders based on predefined criteria. The responder and low-responder groupswere then compared at various time points. Results. Forty-three eyes were included. Regarding VA, 27.9% were low-responders after the loading phase and 30.2% at the end of the study. For CRT, 34.9% were low-responders after the loading phase versus 27.9% at the end of the study. 75% of patients that were VA low-responders and 73.3% of CRT low-responders after loading phase remained low-responders at the end of the study. Conclusion. Approximately 30% of patients showed low response to ranibizumab after the loading phase and after 1 year of treatment. Two-thirds of patients that were low-responders after the loading phase remained low-responders after 1 year. pubtype: Academic Journal doctype: diagnostic images pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|